Genmab — December 2017
-
Flere analytikere har allerede været ude og fastholde deres kursmål for aktien som følge af nattens præsentation. Danske Bank fastholder en købsanbefaling af aktien og et kursmål på 1620, ABG Sundal Collier anbefaler også at købe aktien og fastholder et kursmål på 1570, Jefferies holder fast i sin købsanbefaling og et kursmål på 1700, mens Kempen & Co., der også har en købsanbefaling, fortsat har et kursmål på 1700.
-
from Q3 transcript: And then at the level of guidance for 2018, last year, Peter, we have actually flagged up some soft guidance at the R&D update in December, and we will probably do the same this year.
So you have to wait a little bit more than a month, probably 1.5 months, to hear more color from that
-
Det lyder noget mærkeligt, at Jan repeatedly taler om, at analytikerne ligger med for lavt topsalg - og man så selv ligger markant under på den korte guidance
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind